Compounds > 1-stearoyl-2-arachidonoylglycerol
Page last updated: 2024-08-02 00:35:35

1-stearoyl-2-arachidonoylglycerol

Description

1-stearoyl-2-arachidonoylglycerol : A 1,2-diglyceride in which the acyl groups at positions 1 and 2 are specifed as stearoyl and arachidonoyl respectively. [CHeBI]

Cross-References

ID SourceID
PubMed CID14345637
PubMed CID6438587
SCHEMBL ID1412343
SCHEMBL ID1009384
CHEBI ID83288
CHEBI ID75728
MeSH IDM0204123

Synonyms (53)

Synonym
1-stearoyl-2-arachidonoyl-sn-glycerol, ~98%, suitable for stimulation of protein kinase c derived from liver cells, liquid
1-stearoyl-2-arachidonoylglycerol
CHEBI:83288
1-hydroxy-3-(octadecanoyloxy)propan-2-yl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
1-octadecanoyl-2-(5z,8z,11z,14z)-eicosatetraenoylglycerol
1-octadecanoyl-2-(5z,8z,11z,14z)-icosatetraenoylglycerol
SCHEMBL1412343
Q27156731
(1-hydroxy-3-octadecanoyloxypropan-2-yl) (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
1-stearin-2-arachidonin-sn-glycerol
gtpl2437
dg(18:0_20:4)
dg(18:0/20:4/0:0)[iso2]
1-octadecanoyl-2-(5z,8z,11z,14z-eicosatetraenoyl)-sn-glycerol
LMGL02010111
dg(18:0/20:4(5z,8z,11z,14z)/0:0)[iso2]
IDI1_033877
BSPBIO_001407
1-stearoyl-2-arachidonoyl-sn-glycerol
NCGC00161335-01
NCGC00161335-02
NCGC00161335-03
65914-84-3
1-stearoyl-2-arachidonoyl-glycerol
HMS1989G09
BML2-F09
HMS1791G09
HMS1361G09
[(2s)-1-hydroxy-3-octadecanoyloxypropan-2-yl] (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
(2s)-1-hydroxy-3-(octadecanoyloxy)propan-2-yl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
dag(18:0/20:4omega6)
dag(18:0/20:4)
(2s)-1-hydroxy-3-(stearoyloxy)propan-2-yl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
dg(18:0/20:4(5z,8z,11z,14z)/0:0)
CHEBI:75728
dg(18:0/20:4omega6)
dg(18:0/20:4(omega-6)/0:0)
diacylglycerol(18:0/20:4omega6)
diacylglycerol(18:0/20:4)
5,8,11,14-eicosatetraenoic acid, 1-(hydroxymethyl)-2-((1-oxooctadecyl)ethyl) ester, (s-(all-z))-
SCHEMBL1009384
HMS3402G09
AKOS027379145
dg(18:0/20:4w6)
dg(18:0/20:4n6)
dag(18:0/20:4w6)
diacylglycerol(18:0/20:4w6)
dag(18:0/20:4n6)
Q27088683
diacylglycerol(18:0/20:4n6)
HY-131897
DTXSID901286391
CS-0142415

Drug Classes (2)

ClassDescription
1,2-diglyceride
1,2-diacyl-sn-glycerol

Pathways (30)

1-stearoyl-2-arachidonoylglycerol is involved in 30 pathway(s), involving a total of 151 unique proteins and 445 unique compounds

PathwayProteinsCompounds
Activation of PKC Through G Protein-Coupled Receptor46
Phosphatidylcholine Biosynthesis PC(18:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z))516
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:0)514
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:0)515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:0)515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/24:0)515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z))514
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:4(5Z,8Z,11Z,14Z)) | PE(18:0/20:4(5Z,8Z,11Z,14Z))617

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247		A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
ISSN: 1464-3405		Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
ISSN: 1872-9096		High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346590Human TRPC6 (Transient Receptor Potential channels)1999Nature, Jan-21, Volume: 397, Issue:6716
ISSN: 0028-0836		Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol.
AID1346613Mouse TRPC2 (Transient Receptor Potential channels)2003Neuron, Oct-30, Volume: 40, Issue:3
ISSN: 0896-6273		A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction.

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (33.33)18.2507
2000's9 (33.33)29.6817
2010's6 (22.22)24.3611
2020's3 (11.11)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
1,2-didecanoylglycerol
0
1,2-diglyceride;
decanoate ester		00low000000
methacycline
0
1,2-diglyceride00low000000
dimyristoyl diglyceride
0
1,2-diglyceride;
tetradecanoate ester		00low000000
1,2-dihexanoylglycerol
0
1,2-diglyceride00low000000
1-oleoyl-2-acetylglycerol
0
1,2-diglyceride00low000000
1,2-dioctanoylglycerol
0
1,2-diacyl-sn-glycerol;
dioctanoylglycerol		00low000000
1-palmitoyl-2-oleoyl-sn-glycerol
0
1,2-diacyl-sn-glycerol;
1-palmitoyl-2-oleoylglycerol		mouse metabolite00low000000
1-stearoyl-2-linoleoyl-sn-glycerol
0
1,2-diacyl-sn-glycerol;
diacylglycerol 36:2		mouse metabolite00low000000
1-stearoyl-2-oleoyl-sn-glycerol
0
1,2-diacyl-sn-glycerol;
1-stearoyl-2-oleoylglycerol;
diacylglycerol 36:1		mouse metabolite00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
2-aminoethoxydiphenyl borate
1
organoboron compound;
primary amino compound		calcium channel blocker;
IP3 receptor antagonist;
potassium channel opener		2003200321.0low000100
1,2-dioctanoylglycerol
1
1,2-diacyl-sn-glycerol;
dioctanoylglycerol		2003200321.0medium000100
1-stearoyl-2-linoleoyl-sn-glycerol
1
1,2-diacyl-sn-glycerol;
diacylglycerol 36:2		mouse metabolite1999199925.0medium001000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
1,2-dioctanoylglycerol
2
1993200127.0low001100
chloroquine
1
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		1993199331.0low001000
r 59022
2
diarylmethane1993200923.0low001100
1-(5-isoquinolinesulfonyl)-2-methylpiperazine
1
isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor2000200024.0low001000
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
1
chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector		2009200915.0low000100
1,6-bis(cyclohexyloximinocarbonyl)hexane
2
carbamate ester;
organonitrogen compound		1993199331.0low002000
ro 31-8220
1
imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor1993199331.0low001000
sodium fluoride
1
fluoride saltmutagen2009200915.0low000100
thiazoles
2
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		1993200923.0low001100
manganese
1
elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient		2001200123.0low000100
cadmium
1
cadmium molecular entity;
zinc group element atom		202320231.0low000001
tiletamine hydrochloride
2
1993199331.0low002000
vanadates
1
trivalent inorganic anion;
vanadium oxoanion		EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor		2009200915.0low000100
methacycline
2
1,2-diglyceride2008200915.5low000200
pentafluorobenzoyl chloride
1
acyl chloride;
perfluorinated compound		chromatographic reagent1996199628.0low001000
betadex
1
cyclodextrin2012201212.0low000010
arachidonic acid
3
icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite		1993199331.0low003000
r 59949
1
diarylmethane2009200915.0low000100
orlistat
1
beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor		1993199331.0low001000
genistein
1
7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor		2009200915.0low000100
glyceryl 2-arachidonate
1
2-acylglycerol 20:4;
endocannabinoid		human metabolite201520159.0low000010
1-palmitoyl-2-oleoyl-sn-glycerol
2
1,2-diacyl-sn-glycerol;
1-palmitoyl-2-oleoylglycerol		mouse metabolite1993201221.5high001010
strontium
1
alkaline earth metal atom2001200123.0low000100
1-oleoyl-2-acetylglycerol
2
1,2-diglyceride1993200127.0low001100
1-stearoyl-2-oleoyl-sn-glycerol
1
1,2-diacyl-sn-glycerol;
1-stearoyl-2-oleoylglycerol;
diacylglycerol 36:1		mouse metabolite2012201212.0medium000010
piperidines
1
2009200915.0low000100
okadaic acid
1
ketal2009200915.0low000100
cyclosporine
1
2009200915.0low000100
guanosine triphosphate
1
guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor		1993199331.0low001000
guanosine 5'-o-(3-thiotriphosphate)
1
nucleoside triphosphate analogue2009200915.0low000100
pyrimidinones
2
1993200923.0low001100
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Congenital Zika Syndrome0
1
202020204.0low000010
Disease Models, Animal0
1
202020204.0low000010
Encephalitis, Polio0
1
2011201113.0low000010
Poliomyelitis0
1
2011201113.0low000010
Zika Virus Infection0
1
202020204.0low000010
Acute Liver Injury, Drug-Induced0
1
202320231.0low000001
Adrenal Cancer0
1
2001200123.0low000100
Aging0
1
2011201113.0low000010
Chemical and Drug Induced Liver Injury0
1
202320231.0low000001
Pheochromocytoma0
1
2001200123.0low000100
Pheochromocytoma, Extra-Adrenal0
1
2001200123.0low000100
Sensitivity and Specificity0
1
1996199628.0low001000